Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 27,120 24 apr 2024 17:35
  • 0,000 (0,00%) Dagrange 27,100 - 27,760
  • 86.317 Gem. (3M) 80,8K

Galapagos juli 2019

5.838 Posts
Pagina: «« 1 ... 286 287 288 289 290 ... 292 »» | Laatste | Omlaag ↓
  1. forum rang 7 A3aan 31 juli 2019 13:15
    LaGala doet alsof ze bijna niets weet van de beurs, maar intussen wel transacties vermelden die professionals doen met wisselen op de beurs in New Tork en Amsterdam. Weet van de hoed en de rand. Die dame heeft geen advies nodig. Ze geeft verkapt advies. Of wel ze geeft zich zelf regelmatig een pluim en ze solliciteert naar pluimen van andere forumbezoeken. Ik geef haar de gouden pluim! Leuk hè?
  2. [verwijderd] 31 juli 2019 14:27
    quote:

    Föhn schreef op 30 juli 2019 10:54:

    Dat moneymaker geen fans had op het Gala forum dat wist ik, maar check deze bedreiging eens op het Fugro forum. Hier word je voor minder geschorst..

    www.iex.nl/Forum/Topic/1357826/260/Fu...
    @Fohn,
    Bedankt om gisteren deze link te posten naar het fugro forum ivm die 'ruzie'.
    Ik heb daar gisteren om 16.30 snel nog bakje aandelen van fugro gekocht :-D
  3. Prijzengala 31 juli 2019 14:40
    Ik ben vast op Gala en verwacht voor de toekomst nog mooie pb-tjes.
    Heb nu een vast aantal aandelen die ik op termijn nog wat wil uitbreiden.
    Zoals, ik meende Toert, soms als mogelijkheid noemde, is met een plukje aandelen wat proberen te handelen.
    Gisteren 300 gekocht voor 158 en vanmorgen kunnen slijten voor 160.
    Daarna maar weer een kooporder opgeven voor 158.
    Wellicht ook iets voor jou Legala, dan ben je toch nog wat bezig zonder dat je je druk hoeft te maken over je 'vaste' pluk aandelen.
  4. forum rang 4 holenbeer 31 juli 2019 14:45
    Uit de CC van Gilead:

    Dan O'Day, Gilead:

    So first on Galapagos, it’s fresh news. Earlier this month we announced an exciting new collaboration with Galapagos. As you know, Galapagos is a highly productive R&D engine. They have seven medicines now in clinical development including filgotinib, which has a very comprehensive of life cycle program. And they have more than 20 medicines now in preclinical and their model has been very productive at producing new candidates for the clinic every year. And of course with our increased investments we would expect that to even increase in the future.
    This is a really unique collaboration because it combines complementary strengths between Gilead and Galapagos and very importantly and, as you know, we structured this to allow Galapagos to remain independent. Many of you know my past. I'm a big believer that innovation requires independence, I think to be preserved. And the structure of this deal allows us to preserve the great science and talent at Galapagos. They can invest and innovate to accelerate the progress based upon our investments. And in return we have an exclusive access right to their proven drug discovery platform.
    ….
    So secondly, on filgotinib, as you know now based upon a meeting with the agency we intend to file for U.S. approval for filgotinib later this year in rheumatoid arthritis based upon our discussions with the FDA. We will also be filing in the EU really imminently at this stage, so overall very good news on the path for filgotinib. I had the chance actually recently to attend the EULAR meeting, the Annual European Congress of Rheumatology in Madrid so I can get a first-hand view of the enthusiasm among physicians and thought leaders about the profile of filgotinib and the potential it has to be a best-in-class among the JAK1 inhibitors
  5. forum rang 4 holenbeer 31 juli 2019 14:48
    Daarna Johanna Mercier - Chief Commercial Officer, Gilead

    So that's the first real growth opportunity both in HIV treatment as well as in PrEP. The second one is around filgotinib.

    I really see commended potential in filgotinib and the teams you can imagine they're really hard at work in preparing the launch of this medicine. It's a high priority for me and the team and the whole organization. Although, it's a very competitive space and we know that, we truly have an opportunity to make a difference in the lives of people living with RA and potentially even other inflammatory indication as these are just such debilitating diseases.

    And yes there are numerous treatments on the market for RA. However, many patients aren't actually helped by the therapies that are currently available. The FINCH studies highlight the strong efficacy and tolerability results of filgotinib in different patient types. Filgotinib a JAK1 specific inhibitor could actually answer a clear unmet need in the marketplace for an efficacious and safe oral agent. So, still to come on that, and obviously more to come on the filing in the second half of this year.
  6. forum rang 4 holenbeer 31 juli 2019 14:57
    Dan O’Day:
    Now moving forward, I mean, obviously our emphasis is on growth it's on long-term growth. It's on our ability to shape that R&D portfolio into an area where we have a good number of innovative medicines balanced across our stages of development. As we spoke about last time, one of the areas that we really need to continue to strengthen is our late-stage portfolio as well.
    And I do think that the collaboration with Galapagos and some of the acceleration of molecules that we have within Gilead will help us to strengthen that late-stage portfolio. I remind you with Galapagos they have two products that are in later stage; one for IPF and one for osteoarthritis in addition to the broad program around Filgotinib.


    And we'll continue to supplement that with innovation from the outside, innovation network like Galapagos. Secondarily, on Galapagos in particular, I think, it's probably the best way to put it into context and I said this on the call previously with Galapagos, it's with the collaboration with Galapagos we essentially double our research capacity. And what does that mean? I mean, we've got roughly the same number of scientific colleagues across the two organizations.
    In fact Galapagos will be increasing their number to get a little closer to what we have at Gilead, but it provides with two sources of early-stage discovery input into our late-stage portfolio. And I think that's very exciting because if we can get two highly productive research engines speeding the late-stage portfolio that speaks well for kind of the future of our portfolio as we move forward.

    I can say that as we partner with Galapagos, the respect and admiration from a scientific perspective between Gilead and Galapagos was very high and that's what led me with confidence to move forward with the team in striking that deal.
    So, we will be driven by science for sure. We'll focus on the areas of expertise that we have today. I mean that's HIV, oncology, liver disease, inflammation, and the intersections between those two.
    To your point, I mean I don't think we'll have a one-size-fits-all strategy for bringing innovation into the company. I think that the Galapagos structure was the right structure for that collaboration. It allowed independence, it allowed us to secure our investment, it allowed us rights to everything that comes out of that investment, and therefore, that collaboration was fit for purpose for that particular transaction.

    John McHutchison
    Sure. So, first of all to start off with filgotinib, getting to the issue of -- issues across all thrombotic events, we are still very pleased with the results across all those events, and don't really see anything that would change our perspective on that compared to the specific data that we've presented already.
    Moving on to the Galapagos compound, as you might imagine, we looked very carefully at all of the available data in the IPF program. We have quite a bit of experience in IPF ourselves with prior programs at Gilead as well. And we saw that the data really provided the confidence to Galapagos to be able to move ahead and we share that confidence with them.

  7. [verwijderd] 31 juli 2019 15:05
    quote:

    Prijzengala schreef op 31 juli 2019 14:40:

    Ik ben vast op Gala en verwacht voor de toekomst nog mooie pb-tjes.
    Heb nu een vast aantal aandelen die ik op termijn nog wat wil uitbreiden.
    Zoals, ik meende Toert, soms als mogelijkheid noemde, is met een plukje aandelen wat proberen te handelen.
    Gisteren 300 gekocht voor 158 en vanmorgen kunnen slijten voor 160.
    Daarna maar weer een kooporder opgeven voor 158.
    Wellicht ook iets voor jou Legala, dan ben je toch nog wat bezig zonder dat je je druk hoeft te maken over je 'vaste' pluk aandelen.
    Ik doe dat met opties. als je dan toch bezig bent, kan je beter werken met iets dat meer opbrengt (of waarmee je meer verliest).

    Daardoor blijf ik lekker weg van mijn aandeeltjes.

    Doch, als de opties ferm opgebracht hebben (zoals in de laatste weken), dan koop ik wat gala bij. Maar, niet alleen gala, heb ook wat corona-lotus en wat orsted bijgekocht.

    Heb liever dat dat speeldeel niet boven de 5% gaat.
5.838 Posts
Pagina: «« 1 ... 286 287 288 289 290 ... 292 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links